These innovative compounds represent a significant advancement in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://caoimheitug574367.like-blogs.com/38940856/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide